Disease Domain | Count |
---|---|
Infectious Diseases | 18 |
Neoplasms | 4 |
Hemic and Lymphatic Diseases | 2 |
Nervous System Diseases | 1 |
Immune System Diseases | 1 |
Top 5 Drug Type | Count |
---|---|
Small molecule drug | 14 |
Prophylactic vaccine | 3 |
Chemical drugs | 2 |
Monoclonal antibody | 2 |
Genetically engineered subunit vaccine | 2 |
Target |
Mechanism SARS-CoV-2 S protein inhibitors [+1] |
Active Org. |
Originator Org. |
Active Indication |
Inactive Indication- |
Drug Highest PhasePhase 2 |
First Approval Ctry. / Loc.- |
First Approval Date- |
Target |
Mechanism CpPI(4)K inhibitors |
Active Org. |
Originator Org. |
Active Indication |
Inactive Indication- |
Drug Highest PhasePhase 1 |
First Approval Ctry. / Loc.- |
First Approval Date- |
Target- |
Mechanism Ribosome inhibitors |
Active Org. |
Originator Org. |
Active Indication |
Inactive Indication- |
Drug Highest PhasePreclinical |
First Approval Ctry. / Loc.- |
First Approval Date- |
Start Date01 Mar 2025 |
Sponsor / Collaborator |
Start Date15 Feb 2025 |
Sponsor / Collaborator |
Start Date01 Jan 2025 |
Sponsor / Collaborator |
Drug(Targets) | Indications | Global Highest Phase |
---|---|---|
4'-Fluorouridine ( RdRp ) | Respiratory Syncytial Virus Infections More | Preclinical |
GHP-88309 ( Viral polymerase ) | Respirovirus Infections More | Preclinical |
B-COBRA HA vaccines(University of Georgia) ( hemagglutinin ) | Influenza B virus infection More | Preclinical |
ALN-FLU01 | Influenza A virus infection More | Preclinical |
KDU-731 ( CpPI(4)K ) | Cryptosporidiosis More | Preclinical |